RMD:NYE-ResMed Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 243.02

Change

-1.38 (-0.56)%

Market Cap

USD 37.59B

Volume

1.11M

Analyst Target

USD 184.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

-0.90 (-0.38%)

USD 68.65B
ALC Alcon AG

-1.24 (-1.31%)

USD 46.87B
BAX Baxter International Inc

-0.13 (-0.36%)

USD 18.36B
AVTR Avantor Inc

-0.06 (-0.27%)

USD 15.33B
ATR AptarGroup Inc

+0.33 (+0.20%)

USD 11.25B
TFX Teleflex Incorporated

-1.22 (-0.52%)

USD 11.21B
BLCO Bausch + Lomb Corp

-0.32 (-1.54%)

USD 7.32B
STVN Stevanato Group SpA

+0.08 (+0.43%)

USD 4.94B
WRBY Warby Parker Inc

+0.20 (+1.18%)

USD 2.09B
INFU InfuSystems Holdings Inc

-0.19 (-3.01%)

USD 0.15B

ETFs Containing RMD

EKG First Trust Nasdaq Lux Di.. 7.81 % 0.00 %

+0.04 (+-0.08%)

USD 2.49M
EDOC:AU BetaShares Digital Health.. 7.69 % 0.00 %

+0.18 (+-0.08%)

N/A
EDOG:LSE Global X Telemedicine & D.. 4.92 % 0.00 %

+0.05 (+-0.08%)

USD 0.38M
MCSE Martin Currie Sustainable.. 4.88 % 0.00 %

-0.24 (-0.08%)

N/A
EDOC:LSE Global X Telemedicine & D.. 4.85 % 0.00 %

+0.05 (+-0.08%)

USD 3.69M
DDOC:XETRA Global X Telemedicine & D.. 4.68 % 0.00 %

+0.03 (+-0.08%)

USD 5.39M
DDOC:F Global X Telemedicine & D.. 4.68 % 0.00 %

-0.03 (-0.08%)

USD 4.62M
FDOC:LSE Fidelity Digital Health U.. 4.58 % 0.00 %

N/A

USD 3.02M
FDHT 4.28 % 0.00 %

N/A

N/A
EDOC:SW Global X Telemedicine & D.. 4.25 % 0.00 %

+0.09 (+-0.08%)

N/A
FDHT:XETRA Fidelity Digital Health U.. 4.19 % 0.00 %

-0.03 (-0.08%)

N/A
FAIR:AU BetaShares Australian Sus.. 3.85 % 0.00 %

-0.16 (-0.08%)

USD 1.50B
EX20:AU BetaShares Australian Ex-.. 2.48 % 0.00 %

-0.11 (-0.08%)

USD 0.27B
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.36 % 0.00 %

-0.07 (-0.08%)

N/A
FXH First Trust Health Care A.. 2.25 % 0.63 %

+0.33 (+-0.08%)

USD 1.18B
MEDTE:PA BNP Paribas Easy ECPI Glo.. 2.21 % 0.00 %

-0.07 (-0.08%)

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.21 % 0.00 %

-0.06 (-0.08%)

N/A
JKH iShares Morningstar Mid-C.. 0.00 % 0.30 %

N/A

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

+0.01 (+-0.08%)

USD 0.04B
IMCG iShares Morningstar Mid-C.. 0.00 % 0.00 %

-0.29 (-0.08%)

N/A
VCAV:XETRA VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

USD 0.01B
CVGB:LSE VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

USD 2.24M
CAVE:LSE VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

N/A
CAVE:SW VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -82.34% 5% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.34% 5% F 8% B-
Trailing 12 Months  
Capital Gain -79.36% 5% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -79.36% 5% F 7% C-
Trailing 5 Years  
Capital Gain -79.40% 6% D- 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -79.40% 6% D- 11% F
Average Annual (5 Year Horizon)  
Capital Gain 4.52% 42% F 52% F
Dividend Return 5.35% 47% F 47% F
Total Return 0.82% 44% F 19% F
Risk Return Profile  
Volatility (Standard Deviation) 29.82% 68% D+ 36% F
Risk Adjusted Return 17.93% 58% F 36% F
Market Capitalization 37.59B 86% B+ 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.